Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Plus Therapeutics ( (PSTV) ) is now available.
On June 3, 2025, Plus Therapeutics was notified by the Nasdaq Listing Qualifications Department that it failed to meet the minimum stockholders’ equity requirement of $2.5 million, with a reported deficit of $23,641,000 as of March 31, 2025. Consequently, Nasdaq planned to delist the company’s securities unless an appeal was made. Following a hearing on July 15, 2025, the company was granted continued listing on July 22, 2025, provided it meets specific conditions by August 14, 2025, and September 8, 2025, including maintaining a minimum stock price and demonstrating compliance with equity requirements.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
Plus Therapeutics faces significant financial challenges with negative equity and ongoing losses. While there is some positive technical momentum, the valuation remains unattractive due to a negative P/E ratio and no dividend yield. Corporate events indicate strategic efforts to improve financial health but also highlight risks of potential delisting.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Average Trading Volume: 31,286,313
Technical Sentiment Signal: Sell
Current Market Cap: $44.21M
For an in-depth examination of PSTV stock, go to TipRanks’ Overview page.